Biological Warfare
Ankney B. Iraq possessed large biological research program, UN team says. US Med 1992; 28:3, 40-41.
Berezuk G, McCarty G. Investigational drugs and vaccines fielded in support of Operation Desert Storm. Mil Med 1992; 157:404-406.
Butler D. Admission on Gulf War vaccines spurs debate on medical records. Nature 1997; 390:3-4.
Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM, Jr. Biological warfare: a historical perspective. JAMA 1997; 278 (5):412-417.
Cole LA. Risk and biological defense program. Physicians for Social Responsibility Quarterly 1992; 2:40-50.
Critchley EM. Botulism and Gulf War syndrome. Lancet 1996; 347 (9014):1561.
Danzig R, Berkowsky PB. Why should we be concerned about biological warfare? JAMA 1997; 278 (5):431-432.
Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278 (5):399-411.
Frisina M. A healing-killing conflict in military research? Hastings Cent Rep 1989; 19 (5):2.
Fullerton CS, Ursano RJ. Health care delivery in the high-stress environment of chemical and biological warfare. Mil Med 1994; 159 (7):524-528.
Glass N. From mustard gas to biowarfare�Congress tackles military medicine [news]. Lancet 1998; 351 (9122):1340.
Heden C-G. The 1991 Persian Gulf War: implications for biological arms control. Ann N Y Acad Sci 1992; 666:1-8.
Hepburn NC, Brooks TJG. An outbreak of chickenpox in a military field hospital-the implications for biological warfare. J R Soc Med 1991; 84:721-722.
Huxsoll DL. Narrowing the zone of uncertainty between research and development in biological warfare defense. Ann N Y Acad Sci 1992; 666:177-190.
Huxsoll DL, Parrott CD, Patrick WCD. Medicine in defense against biological warfare. JAMA 1989; 262 (5):677-679.
Lebeda FJ. Deterrence of biological and chemical warfare: a review of policy options. Mil Med 1997; 162 (3):156-161.
Marwick C. Defense appears to have advantage over offense presently in biological warfare. JAMA 1991; 265 (6):700.
Metzger JF, Lewis Jr GE. Human-derived immune globulins for the treatment of botulism. Rev Infect Dis 1979; 1 (4):689-692.
Middlebrook JL. Contributions of the US Army to botulinum toxin research. In: Das Gupta B, ed. New York: Plenum Press; 1993.
Morris K. US anthrax-vaccine producer saved for now. Lancet 1998; 351 (9103):657.
Nass M. Biological warfare. Lancet 1998; 352 (9126):491-492.
Nettleman MD. Biological warfare and infection control. Infect Control Hosp Epidemiol 1991; 12 (6):368-372.
Sapir M. Biological warfare and the "Hiroshima" issue of JAMA [letter; comment]. JAMA 1998; 279 (4):274-275.
Schwarz PJ, Arnon SS. Botulism immune globulin for infant botulism arrives�one year and a Gulf War later. West J Med 1992; 156:197-198.
Sharp TW, Brennan RJ, Keim M, Williams RJ, Eitzen E, Lillibridge S. Medical preparedness for a terrorist incident involving chemical or biological agents during the 1996 Atlanta Olympic Games. Ann Emerg Med 1998; 32 (2):214-23.
Sidel VW. Weapons of mass destruction: The greatest threat to public health. JAMA 1989; 262 (5):680-682.
Simon JD. Biological terrorism: preparing to meet the threat. JAMA 1997; 278 (5):428-430.
Steffen R, Mellin J, Woodall JP, et al. Preparation for emergency relief after biological warfare. J Infect 1997; 34 (2):127-132.
Ursano RJ. Combat stress in the chemical and biological warfare environment. Aviat Space Environ Med 1988; 59 (12):1123-1124.
Wiener SL. Strategies for the prevention of a successful biological warfare aerosol attack. Mil Med 1996; 161 (5):251-256.
Zilinskas RA. Iraq�s biological weapons. The past as future? JAMA 1997; 278 (5):418-424.